{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000612","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.638644+00:00","generated_at":"2026-06-04T07:37:48.573973+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vivani Medical shifts focus to GLP-1 obesity implants; Q4 net loss $6.0M","bullets":["Cash and equivalents $22.0M as of Dec 31, 2023, down from $46.4M; $15M March 2024 financing extends runway into H2 2025.","Full-year 2023 net loss $25.7M vs $13.9M in 2022; R&D expenses rose 20% to $17.0M.","Positive preclinical data: NPM-115 (exenatide) showed ~20% weight loss in obese mice, comparable to semaglutide.","Daniel Bradbury appointed to Board; led Amylin's approval of once-weekly GLP-1 Bydureon.","Anticipates NPM-115 IND filing in H2 2024 and NPM-119 clinical hold response in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000612","json":"https://secwatch.observer/filing/0001753926-24-000612.json","markdown":"https://secwatch.observer/filing/0001753926-24-000612.md","text":"https://secwatch.observer/filing/0001753926-24-000612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000612/0001753926-24-000612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000612/g084147_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:37:48.573973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}